This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Llorente-Cortés, V. Articles by Badimon, L. Search for Related Content PubMed PubMed Citation Articles by Llorente-Cortés, V. Articles by Badimon, L. Related Collections Pathophysiology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1572.)
© 2000 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

LDL Receptor–Related Protein Mediates Uptake of Aggregated LDL in Human Vascular Smooth Muscle Cells

Vicenta Llorente-Cortés; José Martínez-González; Lina Badimon

From the Cardiovascular Research Center, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Correspondence to Prof Lina Badimon, IIBB-CSIC, C/Jordi Girona 18-26, 08034 Barcelona, Spain. E-mail lbmucv{at}cid.csic.es

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Foam cell formation is a key event in the onset and progression of atherosclerotic lesions. We have previously reported that internalization of aggregated low density lipoproteins (agLDLs) by vascular smooth muscle cells (VSMCs) produces cholesteryl ester (CE) accumulation in these cells. The aim of this study was to analyze whether the low density lipoprotein receptor–related protein (LRP) mediates the uptake of agLDL by VSMCs. First, immunocytochemistry and fluorescence microscopic analysis with the use of anti-LRP antibodies indicated that there was a high expression of LRP in VSMCs. Confocal microscopic analysis with the use of agLDLs labeled with fluorochrome 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine and anti-LRP antibodies showed the colocalization of agLDL and LRP. The second approach was to analyze the effect of LRP ligands on agLDL internalization; lactoferrin strongly inhibited CE accumulation from agLDLs (85.0±5.7% at 25 µg/mL) by impairing agLDL binding. Coincubation of agLDL with anti-LRP antibodies decreased in a dose-dependent manner agLDL-derived CE accumulation (from 20% at 12.5 µg/mL to 80% at 50 µg/mL). The third approach was to evaluate whether antisense LRP oligodeoxynucleotides were able to block agLDL internalization. Treatment of VSMCs with 5 µmol/L antisense LRP oligodeoxynucleotides reduced agLDL-derived CE accumulation by 84±2%. In conclusion, these results from immunologic, biochemical, and molecular interventions demonstrate that LRP mediates the binding and internalization of agLDL in human VSMCs. Because LRP is highly expressed in VSMCs and the uptake of 1 LDL aggregate amounts to the deposition of several hundreds of LDL particles, the uptake of agLDL through LRP could have a crucial role for lipid deposition in VSMCs.

Key Words: aggregated LDL • cholesteryl ester accumulation • vascular smooth muscle cells • LDL receptor–related protein • antisense oligodeoxynucleotides

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
One of the main events in the atherogenic process is the accumulation of lipids, mainly cholesteryl esters (CEs).^{1 2} Vascular smooth muscle cells (VSMCs) synthesize proteoglycans, extracellular matrix components involved in the focal deposition of cholesterol-rich particles.^{3 4} The uptake of matrix-retained lipoproteins by VSMCs and macrophages produces CE accumulation and leads to foam cell formation. Macrophages become foam cells through the uptake of diversely modified LDLs, whereas the aggregation of LDLs seems to be a key condition for lipid accumulation in VSMCs.^{5 6 7} Recently, we have shown that accumulation of CEs in VSMCs from in vitro–aggregated LDL (agLDL) is dependent on agLDL concentration and the degree of aggregation.⁸ AgLDLs obtained by vortexing LDL in vitro share structural characteristics with LDL aggregates present in atherosclerotic lesions.^{9 10 11}

In macrophages, phagocytosis and/or scavenger receptors mediate cholesterol accumulation from different types of modified LDL.^{12 13 14 15 16} In human lesions, scavenger receptors are present at high levels in macrophages but not in VSMCs.^{17 18} VSMCs express scavenger receptors only after stimulation with certain growth factors,^{19 20} and a direct involvement of these receptors in VSMC foam cell formation has not been demonstrated. We hypothesized that the LDL receptor–related protein (LRP) was the receptor for agLDL internalization in VSMCs. LRP is present in macrophages and VSMCs from atherosclerotic lesions and from normal vessels.^{17 18 21 22} LRP is a 600-kDa multifunctional endocytic receptor that belongs to the LDL receptor gene family.²³ After synthesis, LRP is cleaved into 515-kDa (-chain) and 85-kDa (ß-chain) subunits.²⁴ LRP has been shown to act as an endocytosis-mediating receptor for several ligands, including lactoferrin,^{25 26} thrombospondin,²⁷ protease–anti-protease complexes,²⁸ plasma lipoproteins such as apoE-enriched VLDL,^{29 30} lipoprotein lipase and lipoprotein lipase-triglyceride–rich lipoprotein complexes,^{31 32 33} and Lp(a).³⁴

Therefore, the aim of the present study was to demonstrate whether LRP was responsible for the binding and internalization of agLDLs in VSMCs. We have found that both antibodies, anti-LRP and lactoferrin (a ligand of LRP), strongly inhibited agLDL binding and CE accumulation derived from agLDL internalization. In addition, VSMCs treated with antisense LRP oligodeoxynucleotides (ODNs) were unable to accumulate CE from agLDL, unlike sense LRP ODN–treated cells. These results seem to support our hypothesis and show that LRP mediates agLDL binding and internalization in VSMCs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Materials
Cell culture medium and reagents were from GIBCO Laboratories. Anti–LDL receptor antibodies (clone C7, RPN 537) were purchased from Amersham. Bovine lactoferrin, ₂-macroglobulin (₂M), and polyinosinic acid (5') were obtained from Sigma Chemical Co. ₂M (1 mg) was activated with 200 mmol/L methylamine-HCl in 50 mmol/L Tris-HCl for 8 hours, pH 8.0 at 25°C.³⁵ The excess of methylamine was removed by dialysis against PBS. Activated ₂M migrated with increased mobility compared with unreacted ₂M, confirming the conformational change.³⁶ 1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI) was purchased from Molecular Probes, Inc. Monoclonal antibodies against LRP chain (A2 MR-2) and LRP ß chain (A2 MRß-2) were kindly provided by Drs S.K. Moestrup and J. Gliemann (University of Aarhus, Aarhus, Denmark). The bicinchoninic acid protein assay was from Pierce.

VSMC Culture
Primary cultures of human VSMCs were obtained from nonatherosclerotic areas of the human aorta from explanted hearts obtained at transplant operations performed at the Hospital de la Santa Creu i Sant Pau. VSMCs were obtained by a modification of the explant technique as we described previously.³⁷ Explants were incubated at 37°C in a humidified atmosphere of 5% CO₂. Outgrown cells were suspended in a solution of trypsin/EDTA and subcultured. They grew in monolayers in medium 199 (M199) supplemented with 5% FCS, 5% human serum, 2 mmol/L L-glutamine, 100 U/mL penicillin G, and 100 µg/mL streptomycin. VSMCs were used between passages 2 and 6. Cell viability was determined by trypan blue exclusion. VSMCs were stained and counted by use of a hemocytometer.

Immunocytochemistry
Cells were seeded in glass coverslips (Laboratory-Tek), grown to confluence, then fixed with methanol for 5 minutes, and blocked with PBS/1% BSA. Afterward, cell monolayers were incubated with primary antibodies diluted in PBS/1% BSA/0.1% Triton X-100 for 2 hours at room temperature. Monoclonal antibodies against smooth muscle cell -actin (1:25 dilution, clone 1A4), von Willebrand factor (1:25 dilution, clone F8/86), -LRP (1 µg/mL), and ß-LRP (1 µg/mL) were used. Coverslips were then washed and incubated with an FITC-conjugated goat anti-mouse IgG (1:20 dilution) for 1 hour in the dark.

Results were evaluated with an Olympus Vanox AHBT3 microscope, and photographs were taken with Kodak Ektachrome (ASA 400) daylight films.

LDL Preparation and DiI Labeling
Human LDLs (density 1.019 to 1.063 g/mL) were obtained from pooled sera of normocholesterolemic volunteers and isolated by sequential ultracentrifugation.³⁸ LDLs were dialyzed against 3 dosages of 200 vol of 150 mmol/L NaCl, 1 mmol/L EDTA, and 20 mmol/L Tris-HCl, pH 7.4, overnight and once against 150 mmol/L NaCl. LDL protein concentration was determined by the bicinchoninic acid method, and cholesterol concentration was determined by a commercial kit (Boehringer). The average total cholesterol content of human LDLs was 2 mg/mg LDL protein. LDLs used in the experiments were <48 hours old. The purity of LDLs was assessed by agarose gel electrophoresis (Paragon System, Beckmann). Thiobarbituric acid reactive substances (TBARS) were measured as an indirect evaluation of lipid peroxidation. TBARS levels were <1.2 mmol malonaldehyde per milligram protein LDL.

LDLs were labeled with DiI by a modification of the method described by Beisiegel et al,³⁰ which involves incubating LDLs (1 mg/mL) in PBS/0.5% BSA with 100 µL DiI in dimethyl sulfoxide (3 mg/mL) for 8 hours at 37°C. No alterations on electrophoretic mobility were detected against unlabeled LDLs.

AgLDLs (unlabeled or DiI-labeled) were prepared by vortexing LDLs in PBS at room temperature. The formation of LDL aggregates by vortexing was monitored by measuring the turbidimetry (absorbance at 680 nm) as previously described.^{8 14 16} The percentage of LDLs in aggregated form was calculated by measuring the fraction of protein recovered in the pellet obtained after centrifugation at 10 000g for 10 minutes.^{8 39 40} This precipitable fraction of LDL vortexed for 4 minutes (100% aggregated) was used in the experiments. TBARS levels against native LDLs remained similar after LDL aggregation.

LDL Binding and Internalization by VSMCs
Arrested cells were prechilled to 4°C and washed with cold M199 containing 1% BSA (M199-BSA). Binding experiments were performed as previously described.^{8 41} VSMCs were incubated with 50 µg/mL DiI–native LDL (DiI-nLDL) or DiI–aggregated LDL (DiI-agLDL) at 4°C for 30 minutes. After binding, medium was removed, and cells were incubated at 37°C for 4 hours in the absence or presence of the different compounds tested. Cells were then washed in M199-BSA containing 100 U heparin/mL for 15 minutes at 4°C with constant shaking, fixed at room temperature for 10 minutes in PBS containing 3% paraformaldehyde and 2% sucrose before staining with Hoechst 33258 colorant (1:2000) for 10 minutes, and washed twice with PBS. Finally, fluorescent photomicrographs were taken in a Olympus Vanox AHBT3 microscope with an excitation filter for rhodamine with the use of Kodak Ektachrome (ASA 400) daylight films.

After DiI-LDL incubation, several samples were stained with anti-LRP ß-chain antibodies to analyze the colocalization of DiI-LDL and LRP. Samples were analyzed by a laser-scanning confocal fluorescence microscope (Leica TCS NT). The software program used was TCSNT, version 1.3.237 (Leica).

Determination of Free and Esterified Cholesterol Content
In the experiments performed to analyze the effect of anti-LRP antibodies, arrested cells were incubated for 18 hours with native LDL or agLDL in the absence or presence of increasing concentrations (12.5, 25, and 50 µg/mL) of anti-LDL receptors, anti-LRP -chain antibodies, or nonimmune IgG. In other experiments, arrested cells were incubated with increasing concentrations (25, 50, or 100 µg/mL) of lactoferrin, ₂M, or polyinosinic acid. At the end of this period, cells were exhaustively washed, twice with PBS, twice with PBS/1% BSA, and twice with PBS/1% BSA/heparin 100 U/mL, before harvesting into 1 mL of 0.15 mol/L NaOH. Lipid extraction and thin-layer chromatography were performed as previously described.^{8 39 40} The spots corresponding to free cholesterol (FC) and esterified cholesterol were quantified by densitometry against the standard curve of cholesterol and cholesterol palmitate, respectively, with the use of a computing densitometer (Molecular Dynamics).

ODN Treatment
Phosphorothioate antisense ODNs were designed to hybridize to the initiation site on the human LRP mRNA. It was a 15-mer (5'-CGGCGGGGTCAGCAT-3') that was complementary to nucleotides 466 to 481 of LRP mRNA. The corresponding sense ODN and a random ODN (5'-TAGCTTGATGTGAGG-3') were used as a control. Fasta analysis (in the Genetic Computer Group package) indicated that these sequences would not hybridize to other receptor sequences (including LDL receptors) in the GenBank database. These ODNs contained the phosphorothioate modification in all positions to avoid degradation by nucleases.⁴² They were synthesized by using phosphoramidite chemistry and purified by high-performance liquid chromatography (MWG Biotech). The lyophilized product was dissolved at a stock concentration of 5 mmol/L in diethylpyrocarbonate-treated water and stored at -20°C.

VSMCs were grown in normal medium and treated with ODNs during the quiescence period (48 hours). Antisense and sense ODNs (5, 10, and 20 µmol/L) were added to the medium at the beginning of the first 24 hours of the arresting period. Then the medium was replaced by a new medium containing the ODNs at the same concentrations and maintained for a further 24 hours. AgLDLs (100 µg/mL) were added to nontreated and to antisense, sense, and random ODN-treated VSMCs 12 hours before ending the second 24 hours of the arresting period. Then the cells were exhaustively washed, photographed, and harvested into 1 mL of 0.15 mol/L NaOH. The determination of FC and CE content was performed as previously described.^{8 40}

Statistical Analysis
Data are expressed as mean±SEM. A Statview (Abacus Concepts) statistical package for the Macintosh computer system was used for all analyses. Multiple groups were compared by 1-factor ANOVA. A value of P<0.05 was considered to be statistically significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
LRP Levels in VSMCs
Immunolabeling of VSMCs with anti-LRP antibodies showed that this receptor is highly expressed in VSMCs (Figure I, which can be found online at http://atvb.ahajournals.org). All nuclei (blue) are surrounded by anti–-subunit or anti–ß-subunit staining (Figure IB and ID). Figure IA and IC shows, in high-magnification photographs, the perinuclear labeling of and ß subunits.

View larger version (24K): [in this window] [in a new window]   Figure 1. Colocalization of agLDL and LRP in VSMCs. Confocal microscopy of VSMCs incubated with antibodies anti-LRP (green) and DiI-nLDL or DiI-agLDL (red). VSMCs were incubated with DiI-nLDL or DiI-agLDL (50 µg/mL) for 30 minutes at 4°C. Cells were then washed and incubated for 4 hours at 37°C. Then VSMCs were washed, fixed, and incubated with anti-LRP ß chain. Photomicrographs show VSMCs incubated with DiI-agLDL and anti-LRP ß chain (A) or DiI-nLDL and anti-LRP ß chain (B). Photomicrographs are representative of 2 different experiments. Magnification x5000.

Colocalization of LRP and DiI-LDL
Confocal microscopy was performed to study the colocalization of agLDL and LRP during the internalization of agLDL by VSMCs. VSMCs were incubated with DiI-nLDL or DiI-agLDL for 30 minutes at 4°C. After removal of unbound LDL, the bound lipoprotein fraction was left to internalize for 4 hours at 37°C. VSMCs were then labeled with anti-LRP ß-chain antibodies as described in Methods. Confocal laser microscopy demonstrated that there is a high colocalization of DiI-agLDL (red) and LRP (green) observed as yellow stain (Figure 1A). In contrast, DiI-nLDL (red) and LRP (green) did not colocalize (Figure 1B).

Comparison of Lactoferrin (Ligand of LRP) and Polyinosinic Acid (Ligand of Scavenger Receptor) on CE Accumulation Derived From AgLDL
VSMCs were coincubated with agLDLs (100 µg/mL) and increasing concentrations (25, 50, and 100 µg/mL) of either lactoferrin, a ligand of LRP, or polyinosinic acid, a ligand of scavenger receptors. Polyinosinic acid only slightly reduced CE accumulation from agLDLs. On the contrary, lactoferrin, at the lowest concentration tested (25 µg/mL), produced an inhibition of 85.0±5.7% (Figure 2). Activated ₂M, at 50 µg/mL, did not have any effect on CE accumulation derived from agLDLs. Preincubation of VSMCs with lactoferrin (25 µg/mL) for 1 hour completely abolished endocytosis of agLDL (Figure II, which can be found online at http://atvb.ahajournals.org), indicating that the decrease in CE accumulation produced by lactoferrin was due to the inhibition of agLDL binding to LRP.

View larger version (37K): [in this window] [in a new window]   Figure 2. Effect of lactoferrin and polyinosinic acid on agLDL-derived CE accumulation in VSMCs. VSMCs were incubated with agLDL (100 µg/µL) and increasing concentrations (25, 50, and 100 µg/mL) of lactoferrin or polyinosinic acid for 18 hours. VSMCs were then exhaustively washed and harvested to measure intracellular FC and CE. A, Thin-layer chromatography showing the bands corresponding to FC and CE of VSMCs incubated with the different concentrations of the tested compounds. B, Bar graph showing the quantification of CE (solid symbols) and FC (open symbols) bands of VSMCs incubated with lactoferrin (circles) or polyinosinic acid (triangles). Results are expressed as microgram cholesterol per milligram protein and are shown as mean±SEM of 3 independent experiments performed in duplicate.

These results indicate that scavenger receptors are not dominant receptors for agLDL uptake in VSMCs and suggest that LRP mediates agLDL uptake.

Comparison of Effect of Anti-LRP Antibodies, Anti-LDL Receptor, and Nonimmune IgG on CE Accumulation Derived From AgLDL
To further analyze whether LRP mediates the uptake of agLDL by VSMCs, we assessed the effect of monoclonal antibodies against the chain of LRP (A2 MR-2)^{43 44} compared with the effect of monoclonal antibodies against LDL receptors (clone C7) or nonimmune IgG. Figure 3 shows that anti-LRP antibodies decreased in a dose-dependent manner the CE accumulation induced by agLDL uptake. In contrast, nonimmune IgG did not show any significant effect. The anti-LDL receptor antibody did not show any significant effect at a concentration of 12.5 or 25 µg/mL. Anti-LDL receptor antibodies decreased CE increase induced by native LDL in a dose-dependent manner (Figure III, which can be found online at http://atvb.ahajournals.org). On the contrary, nonimmune IgG did not show any significant effect.

View larger version (33K): [in this window] [in a new window]   Figure 3. Effect of increasing concentrations of anti-LRP, anti-LDL receptor, and nonimmune IgG on the CE accumulation derived from agLDL uptake. VSMCs were incubated with agLDL (100 µg/mL) and increasing concentrations (12.5, 25, and 50 µg/mL) of monoclonal antibodies anti-LRP, anti-LDL receptor, or nonimmune IgG for 18 hours. After this period, VSMCs were exhaustively washed and harvested for measurement of FC and CE. A, Thin-layer chromatography showing the FC and CE bands corresponding to VSMCs incubated with the different antibody concentrations. B, Line graph showing the quantification of CE bands (solid symbols) and FC (open symbols) in VSMCs incubated with anti-LRP (circles), anti-LDL receptor (triangles), or nonimmune IgG (squares). Results are expressed as micrograms cholesterol per milligram protein and are shown as the mean of 1 experiment performed in triplicate (deviations <5% of the mean do not appear in the computer-originated graphs).

Effect of AgLDL on Cholesterol Content of VSMCs Treated With Antisense LRP ODNs
LRP expression was blocked by antisense LRP ODNs to determine whether agLDL internalization could be suppressed in the treated cells. AgLDL-derived CE accumulation (153±4.41 µg CE per milligram protein) was significantly reduced (84±2% inhibition at 5 µmol/L and 91±5% at 20 µmol/L) in antisense ODN–treated VSMCs (Figure 4) but not in sense ODN– or random ODN–treated cells. FC content was only slightly reduced by antisense ODN treatment. The lack of effect of sense and random ODNs on agLDL binding and CE accumulation support the specificity of antisense ODN treatment. In addition, native LDL–derived CE increase was not diminished by antisense LRP ODN treatment (Figure 5).

View larger version (31K): [in this window] [in a new window]   Figure 4. Effect of antisense LRP ODNs on CE accumulation derived from agLDL uptake in VSMCs. VSMCs were arrested in the absence or presence of increasing concentrations of antisense or sense ODNs for consecutive periods of 24 hours. During the final 12 hours of the second 24-hour ODN treatment, agLDL (100 µg/mL) was added to the incubation medium. Then VSMCs were exhaustively washed and harvested for measurement of FC and CE. A, Thin-layer chromatography showing the FC and CE bands corresponding to VSMCs incubated with antisense or sense ODNs against nontreated VSMCs (control). B, Line graph showing the quantification of CE bands (solid symbols) and FC (open symbols) in VSMCs incubated with increasing concentrations of antisense (circles) or sense (triangles) LRP ODNs. Results are expressed as micrograms cholesterol per milligram protein and are shown as the mean of 1 experiment performed in triplicate (deviations <5% of the mean do not appear in the computer-originated graphs).

View larger version (34K): [in this window] [in a new window]   Figure 5. Effect of antisense LRP ODNs on CE content of VSMCs incubated with native LDL. VSMCs were arrested in the absence or presence of increasing concentrations of antisense or sense ODNs for consecutive periods of 24 hours. During the final 12 hours of the second 24-hour ODN treatment, native LDL (100 µg/mL) was added to the incubation medium. Then VSMCs were exhaustively washed and harvested for measurement of FC and CE. A, Thin-layer chromatography showing the FC and CE bands corresponding to VSMCs incubated with antisense or sense ODNs against nontreated VSMCs (control). B, Line graph showing the quantification of CE bands in VSMCs incubated with increasing concentrations of antisense (circles) or sense (triangles) LRP ODNs. Results are expressed as percentage of control (CE increase induced by native LDL) and are shown as the mean of 1 experiment performed in triplicate (deviations <5% of the mean do not appear in the computer-originated graphs).

Figure 6 shows microphotographs of representative cells after incubation of nontreated and antisense and sense LRP ODN–treated VSMCs with agLDL. Pictures were taken after the first wash with PBS to eliminate agLDL that was not bound. As shown, untreated VSMCs (Figure 6A) had many aggregates of LDL bound (arrows) on the cell surface, whereas antisense LRP ODN–treated (5 µmol/L) VSMCs did not (Figure 6B). Sense ODN–treated (Figure 6C) or random ODN–treated (photography not shown) VSMCs also have many LDL aggregates bound to the cell surface. The ODN treatment of VSMCs did not seem to induce morphological changes of VSMCs.

View larger version (116K): [in this window] [in a new window]   Figure 6. Effect of antisense LRP ODNs on agLDL binding by VSMCs. VSMCs were arrested in the absence (A) or presence of 5 µmol/L antisense ODNs (B) or sense ODNs (C) for consecutive periods of 24 hours. During the final 12 hours of the second 24-hour ODN treatment, agLDL (100 µg/mL) was added to the incubation medium. Then VSMCs were washed with PBS and photographed (magnification x100). Arrows indicate LDL aggregates bound to the cell surface.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Several lipoprotein receptors may be involved in LDL uptake in the arterial wall.^{20 21 22} Among them, the scavenger receptors (highly expressed in macrophages) and LRP (highly expressed in VSMCs) would be candidates for agLDL uptake. In the present study, high concentrations of polyinosinic acid, a ligand of the scavenger receptor, only slightly inhibited agLDL-derived CE accumulation in VSMCs. These results are in agreement with those showing that neither the uptake of LDL aggregates, obtained by vortexing¹³ or binding with proteoglycans,^{5 12} nor the uptake of agLDL isolated from injured aortas^{45 46} is mediated by scavenger receptors. We hypothesized that the particular structure of the binding domain of the LRP, composed of multiple copies of 3 of the 4 structural motifs found in the extracellular binding domain of the LDL receptor,²³ would facilitate the interaction with agLDL, composed of hundreds of LDL particles.^{5 9} Indeed, lactoferrin, a nondissociable ligand for LRP, has been shown to be highly effective in preventing agLDL binding and CE accumulation in the cultured VSMCs at very low concentrations. A similar concentration of lactoferrin has been used by other authors to inhibit the uptake of chylomicron remnants.⁴⁷ The high effectiveness of lactoferrin could be due to the sequestration of LRP by lactoferrin into the endosomes and the impairment of LRP recycling.²⁵ The experiments using DiI-agLDL indicate that, as with other ligands, lactoferrin inhibits the first step of the internalization process, the binding of agLDL to the cell surface. Because in binding experiments, lactoferrin competes with lipoprotein lipase/VLDL, apoE/VLDL, and remnant chylomicrons but not with tissue plasminogen activator/plasminogen activator inhibitor type-1 or ₂-M,^{26 47 48} it is conceivable that agLDL could share the ligand binding site with other LRP lipoprotein ligands.

The uptake of agLDL can be also be blocked by treatment of the cells with antibodies against the LRP chain. These antibodies strongly inhibited CE accumulation, indicating the involvement of the LRP chain on agLDL binding. The antibody concentrations used were similar to those used by other authors to inhibit the uptake of other LRP ligands.^{26 29} It seems that structurally unrelated ligands appear to contain homologous positively charged domains that are involved in receptor binding.^{49 50 51 52} We do not know whether the striking ability of agLDL to induce cholesterol accumulation in VSMCs is due to the presence of various apoB-100 binding sites in each particle or to the configuration of a new LRP-recognizable epitope after LDL modification. There are controversial results concerning the capacity of LRP to interact with apoB-100; Véniant et al⁵³ demonstrated in a mice model that there is no binding of apoB-100 to LRP. However, other authors have demonstrated the specific binding of apoB-100 to purified LRP.⁵⁴

In macrophages, phagocytosis has been considered to be the main mechanism for agLDL uptake, and controversial results have been published concerning the involvement of the classic LDL receptor.^{12 13 14} In VSMCs, we have evidenced that anti-LDL receptor antibodies, which specifically inhibit intracellular CE increase induced from native LDLs, do not have any effect on CE accumulation from agLDL; therefore, the classic LDL receptor does not seem essential for agLDL uptake. These results are in agreement with our previous finding showing a different pattern for DiI-nLDL and DiI-agLDL internalization in VSMCs.⁸ Finally, the involvement of LRP on agLDL binding and internalization has also been demonstrated by the lack of agLDL binding and CE accumulation in antisense LRP ODN–treated VSMCs. From these results, we can conclude that a functional LRP is required for CE accumulation from agLDL in VSMCs. A direct heparan sulfate proteoglycan–mediated internalization, as postulated for apoE-triglyceride–rich lipoprotein particles,⁴¹ seems not to be the main pathway for agLDL in VSMCs. However, it is likely that the process called "ligand transfer" from heparan sulfate proteoglycans to LRP (demonstrated with other LRP ligands)^{55 56} can also occur with agLDL and needs to be investigated.

Our results demonstrate for the first time that in VSMCs, cells with very high levels of LRP expression, LRP mediates the binding and internalization of agLDL and that in the absence of LRP function, VSMCs are unable to accumulate cholesterol. LRP, contrary to the LDL receptor, has multiple binding sites and is not regulated by intracellular cholesterol. Therefore, LRP-mediated endocytosis can be considered as a low-specificity high-capacity mechanism that allows the uptake of large amounts of ligand. Because LRP is highly expressed in atherosclerotic plaques and because subendothelial LDL retention and aggregation are key events in atherogenesis, the uptake of agLDL through LRP could have a crucial role in VSMC-lipid deposition in atherosclerotic plaques.

	Acknowledgments

 
This study was partly funded by Bristol-Myers Squibb/Centro Desarrollo Tecnológico Industrial 96-0035, Fondo Investigación Industrial 98/0715, and Fundación Investigación Cardiovascular Catalana-Occidente. The authors thank the Heart Transplant Team of the Division of Cardiology and Cardiac Surgery and the Blood Bank of Hospital de la Santa Creu i Sant Pau, Barcelona, for their collaboration. The LRP antibodies used in this study were a generous gift from Drs S.K. Moestrup and J. Gliemann, Department of Medical Biochemistry, University of Aarhus, Aarhus, Denmark. The authors also thank Anna Bosch for her assistance with confocal microscopy.

Received September 24, 1999; accepted January 18, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med. 1992;326:242–250.[Medline] [Order article via Infotrieve]

2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and acute coronary syndromes (part II). N Engl J Med. 1992;326:310–318.[Medline] [Order article via Infotrieve]

3. Tabas I, Yueqing L, Brocia RW, Wen Xu S, Swenson TL, Williams KJ. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. J Biol Chem. 1993;268:20419–20432.[Abstract/Free Full Text]

4. Camejo, G, Gunnar F, Rosengren B, Hurt-Camejo E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem. 1993;268:14131–14137.[Abstract/Free Full Text]

5. Tertov VV, Orekhov AN, Sobenin JA, Gabbasov ZA, Popov EG, Yaroslavov AA, Smirnov VN. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res. 1992;71:218–228.[Abstract/Free Full Text]

6. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. Lipoprotein aggregation as an essential step of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun. 1989;163:489–494.[Medline] [Order article via Infotrieve]

7. Nermine A, Ismail E, Alavi MZ, Moore S. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis. 1994;105:79–87.[Medline] [Order article via Infotrieve]

8. Llorente-Cortés V, Martínez-González J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol. 1998;18:738–746.[Abstract/Free Full Text]

9. Guyton JR, Klemp KF, Mims MP. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J Lipid Res. 1991;32:953–961.[Abstract]

10. Aviram M, Maor Y, Keidar S, Hayek T, Oiknine J, Bae EIY, Adler Z, Kertzman V, Milo S. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun. 1995;216:501–513.[Medline] [Order article via Infotrieve]

11. Pentikaïnen MO, Lehtonen EMP, Kovanen PT. Aggregation and fusion of modified low density lipoprotein. J Lipid Res. 1996;37:2638–2649.[Abstract]

12. Vijayagopal P, Glancy DL. Macrophages stimulate cholesteryl ester accumulation in cocultured smooth muscle cells incubated with lipoprotein-proteoglycan complex. Arterioscler Thromb Vasc Biol. 1996;16:1112–1121.[Abstract/Free Full Text]

13. Khoo JC, Miller E, Loughlin MC, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis. 1998;8:348–358.[Abstract/Free Full Text]

14. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JM. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb. 1992;12:1258–1266.[Abstract/Free Full Text]

15. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediate uptake and degradation of acetylated low density lipoprotein producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333–337.[Abstract/Free Full Text]

16. Lougheed M, Steinbrecher UP. Mechanism of uptake of copper oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation. J Biol Chem. 1996;271:11798–11805.[Abstract/Free Full Text]

17. Moestrup SK, Gliemann J, Pallesen G. Distribution of 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269:375–382.[Medline] [Order article via Infotrieve]

18. Luoma J, Hiltunen T, Särkioja T, Moestrup SK, Gliemann J, Kodama T, Nikkari T, Ylä-Herttuala S. Expression of 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions. J Clin Invest. 1994;93:2014–2021.

19. Gong Q, Pitas RE. Synergistic effects of growth factors on the regulation of smooth muscle cell scavenger receptor activity. J Biol Chem. 1995;270:21672–21678.[Abstract/Free Full Text]

20. Pitas RE. Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. J Biol Chem. 1990;265:12722–12727.[Abstract/Free Full Text]

21. Hiltunen TP, Luoma JS, Nikkari T, Ylä-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions. Circulation. 1998;97:1079–1086.[Abstract/Free Full Text]

22. Hiltunen TP, Ylä-Herttuala S. Expression of lipoprotein receptors in atherosclerotic lesions. Atherosclerosis. 1998;137(suppl):S81–S88.

23. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggest that this molecule is a multifunctional receptor. J Biol Chem. 1990;265:17401–17404.[Abstract/Free Full Text]

24. Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kD low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J. 1988;9:1769–1776.[Medline] [Order article via Infotrieve]

25. Meilinger M, Haumer M, Szakmary KA, Steinböck F, Scheiber B, Goldenberg H, Huettinger M. Removal of lactoferrin from plasma is mediated by binding to low density lipoprotein receptor-related protein/2-macroglobulin receptor and transport to endosomes. FEBS Lett. 1995;360:70–74.[Medline] [Order article via Infotrieve]

26. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem. 1992;267:26172–26180.[Abstract/Free Full Text]

27. Mikhailenko I, Kounnas MZ, Strickland DK. Low density lipoprotein receptor-related protein/2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. J Biol Chem. 1995;270:9593–9549.

28. Moestrup SK, Gliemann J. Analysis of ligand recognition by the purified 2-macroglobulin receptor (low density lipoprotein receptor-related protein): evidence that high affinity of 2-macroglobulin-proteinase complex is achieved by binding to adjacent receptors. J Biol Chem. 1995;266:14011–14017.[Abstract/Free Full Text]

29. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived form apolipoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A. 1989;86:5810–5814.[Abstract/Free Full Text]

30. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989;341:162–164.[Medline] [Order article via Infotrieve]

31. Chappel DA, Fry GL, Waknitz MA, Iverius PH, Williams SE, Stickland DK. The low density lipoprotein receptor-related protein/2 macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase. J Biol Chem. 1992;267:25764–25767.[Abstract/Free Full Text]

32. Chappel DA, Fry GL, Waknitz LE, Muhonen LE, Pladet MW, Iverius PH, Strickland DK. Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor-related protein/2-macroglobulin receptor in vitro. J Biol Chem. 1992;268:14168–14175.[Abstract/Free Full Text]

33. Krapp A, Ahle S, Kersting S, Hua Y, Kneser K, Nielsen M, Gliemann J, Beisiegel U. Hepatic lipase mediates the uptake of chylomicrons and ß-VLDL into cells via the LDL receptor-related protein LRP. J Lipid Res. 1996;37:926–936.[Abstract]

34. Reblin T, Niemeier A, Meyer N, Willnow TE, Kronenberg F, Dieplinger H, Greten H, Beisiegel U. Cellular uptake of lipoprotein [a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J Lipid Res. 1997;38:2103–2110.[Abstract]

35. Stouffer GA, LaMarre J, Gonias SL, Owens GK. Activated ₂-macroglobulin and transforming growth factor ß1 induce a synergistic smooth muscle cell proliferative response. J Biol Chem. 1993;268:18340–18344.[Abstract/Free Full Text]

36. Barrett AJ, Brown MA, Sayers CA. The electrophoretically ‘slow’ and ‘fast’ forms of the ₂-macroglobulin molecule. Biochem J. 1979;181:401–418.[Medline] [Order article via Infotrieve]

37. Martínez-González J, Badimon L. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model. Eur J Clin Invest. 1996;26:1023–1032.[Medline] [Order article via Infotrieve]

38. Havel R, Eder H, Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345–1354.

39. Asmis R, Llorente-Cortés V, Gey F. Prevention of cholesteryl ester accumulation in P388 D₁ macrophage-like cells by increased cellular vitamin E depends on species of extracellular cholesterol. Eur J Biochem. 1995;233:171–178.[Medline] [Order article via Infotrieve]

40. Llorente-Cortés V, Martínez-González J, Badimon L. Differential cholesteryl ester accumulation in two human vascular smooth muscle cell subpopulations exposed to aggregated LDL: effect of PDGF-stimulation and HMG-CoA reductase inhibition. Atherosclerosis. 1999;144:335–342.[Medline] [Order article via Infotrieve]

41. Fernández-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaró S. Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: evidence for an LDL receptor-independent internalization pathway. J Lipid Res. 1996;37:464–481.[Abstract]

42. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood. 1998;82:712–736.[Abstract/Free Full Text]

43. Moestrup SK, Kaltoft K, Petersen CM, Pedersen S, Gliemann J, Christensen EI. Immunocytochemical identification of the human ₂-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen. Exp Cell Res. 1990;190:195–203.[Medline] [Order article via Infotrieve]

44. Moestrup SK, Kaltoft K, Sottrup-Jensen L, Gliemann J. The human ₂-macroglobulin contains high affinity calcium binding sites important for receptor conformation and ligand recognition. J Biol Chem. 1990;265:12623–12628.[Abstract/Free Full Text]

45. Morton RE, West GA, Hoff HF. A low density lipoprotein-sized particle isolated from human atherosclerotic lesions is internalized by macrophages via a non-scavenger-receptor mechanism. J Lipid Res. 1986;27:1124–1134.[Abstract]

46. Hoff HF, O’Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb. 1991;11:1209–1222.[Abstract/Free Full Text]

47. Huettinger M, Retzek H, Hermann M, Goldenberg H. Lactoferrin specifically inhibits endocytosis of chylomicron remnants but not -macroglobulin. J Biol Chem. 1992;267:18552–18557.

48. Nykjaer A, Bengtsson-Olivecrona G, Lookene A, Moestrup SK, Petersen CM, Weber W, Beisiegel U, Gliemann J. The ₂-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and B-migrating very low density lipoprotein associated with the lipase. J Biol Chem. 1993;268:15048–15055.[Abstract/Free Full Text]

49. Herz J. The LDL-receptor-related protein: portrait of a multifunctional receptor. Curr Opin Lipidol. 1993;4:107–113.

50. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem. 1994;63:601–637.[Medline] [Order article via Infotrieve]

51. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man: multiple functions of the large family members via interactions with complex ligands. Biol Chem. 1998;379:951–964.[Medline] [Order article via Infotrieve]

52. Neels JG, Horn IR, Van den Berg MM, Pannekoek H, Van Zonneveld A-J. Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor. Fibrinol Proteol. 1998;12:219–240.

53. Véniant MV, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, Herz J, Young SG. Lipoprotein clearance mechanisms in LDL receptor-deficient ‘apo-B48-only’ and ‘apo-B100-only’ mice. J Clin Invest. 1998;102:1559–1568.[Medline] [Order article via Infotrieve]

54. Wu SM, Pizzo SV. Low-density lipoprotein receptor-related protein/₂-macroglobulin receptor on murine peritoneal macrophages mediates the binding and catabolism of low density lipoprotein. Arch Biochem Biophys. 1996;326:39–47.[Medline] [Order article via Infotrieve]

55. Williams KF, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins: roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem. 1992;267:13284–13292.[Abstract/Free Full Text]

56. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest. 1992;90:2013–2021.

This article has been cited by other articles:

				W. Liu, S. Mani, N. R. Davis, N. Sarrafzadegan, P. B. Kavathas, and A. Mani Mutation in EGFP Domain of LDL Receptor-Related Protein 6 Impairs Cellular LDL Clearance Circ. Res., November 21, 2008; 103(11): 1280 - 1288. [Abstract] [Full Text] [PDF]

				T. Padro, E. Pena, M. Garcia-Arguinzonis, V. Llorente-Cortes, and L. Badimon Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain Cardiovasc Res, January 1, 2008; 77(1): 211 - 220. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, T. Royo, O. Juan-Babot, and L. Badimon Adipocyte differentiation-related protein is induced by LRP1-mediated aggregated LDL internalization in human vascular smooth muscle cells and macrophages J. Lipid Res., October 1, 2007; 48(10): 2133 - 2140. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, T. Royo, M. Otero-Vinas, M. Berrozpe, and L. Badimon Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages Cardiovasc Res, June 1, 2007; 74(3): 526 - 536. [Abstract] [Full Text] [PDF]

				L. Hu, L.S.M. Boesten, P. May, J. Herz, N. Bovenschen, M.V. Huisman, J.F.P. Berbee, L.M. Havekes, B.J.M. van Vlijmen, and J.T. Tamsma Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2710 - 2715. [Abstract] [Full Text] [PDF]

				P. Hernandez-Vargas, G. Ortiz-Munoz, O. Lopez-Franco, Y. Suzuki, J. Gallego-Delgado, G. Sanjuan, A. Lazaro, V. Lopez-Parra, L. Ortega, J. Egido, et al. Fc{gamma} Receptor Deficiency Confers Protection Against Atherosclerosis in Apolipoprotein E Knockout Mice Circ. Res., November 24, 2006; 99(11): 1188 - 1196. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, S. Camino-Lopez, P. Costales, and L. Badimon Cholesteryl Esters of Aggregated LDL Are Internalized by Selective Uptake in Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 117 - 123. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes and L. Badimon LDL Receptor-Related Protein and the Vascular Wall: Implications for Atherothrombosis Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 497 - 504. [Abstract] [Full Text] [PDF]

				J. D. Davies, K. L. H. Carpenter, I. R. Challis, N. L. Figg, R. McNair, D. Proudfoot, P. L. Weissberg, and C. M. Shanahan Adipocytic Differentiation and Liver X Receptor Pathways Regulate the Accumulation of Triacylglycerols in Human Vascular Smooth Muscle Cells J. Biol. Chem., February 4, 2005; 280(5): 3911 - 3919. [Abstract] [Full Text] [PDF]

				P. P. E. M. Spijkers, P. da Costa Martins, E. Westein, C. G. Gahmberg, J. J. Zwaginga, and P. J. Lenting LDL-receptor-related protein regulates {beta}2-integrin-mediated leukocyte adhesion Blood, January 1, 2005; 105(1): 170 - 177. [Abstract] [Full Text] [PDF]

				X. Wang, N. Adhikari, Q. Li, and J. L. Hall LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2376 - H2383. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, S. Camino-Lopez, O. Llampayas, and L. Badimon Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells Circulation, July 27, 2004; 110(4): 452 - 459. [Abstract] [Full Text] [PDF]

				S.-y. Morita, M. Kawabe, A. Sakurai, K. Okuhira, A. Vertut-Doi, M. Nakano, and T. Handa Ceramide in Lipid Particles Enhances Heparan Sulfate Proteoglycan and Low Density Lipoprotein Receptor-related Protein-mediated Uptake by Macrophages J. Biol. Chem., June 4, 2004; 279(23): 24355 - 24361. [Abstract] [Full Text] [PDF]

				M. Patel, J. Morrow, F. R. Maxfield, D. K. Strickland, S. Greenberg, and I. Tabas The Cytoplasmic Domain of the Low Density Lipoprotein (LDL) Receptor-related Protein, but Not That of the LDL Receptor, Triggers Phagocytosis J. Biol. Chem., November 7, 2003; 278(45): 44799 - 44807. [Abstract] [Full Text] [PDF]

				C. Rodriguez, B. Raposo, J. Martinez-Gonzalez, V. Llorente-Cortes, G. Vilahur, and L. Badimon Modulation of ERG25 expression by LDL in vascular cells Cardiovasc Res, April 1, 2003; 58(1): 178 - 185. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, S. Sanchez, C. Rodriguez, and L. Badimon Low-Density Lipoprotein Upregulates Low-Density Lipoprotein Receptor-Related Protein Expression in Vascular Smooth Muscle Cells: Possible Involvement of Sterol Regulatory Element Binding Protein-2-Dependent Mechanism Circulation, December 10, 2002; 106(24): 3104 - 3110. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, and L. Badimon Differential Role of Heparan Sulfate Proteoglycans on Aggregated LDL Uptake in Human Vascular Smooth Muscle Cells and Mouse Embryonic Fibroblasts Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1905 - 1911. [Abstract] [Full Text] [PDF]

				V. Llorente-Cortes, M. Otero-Vinas, E. Hurt-Camejo, J. Martinez-Gonzalez, and L. Badimon Human Coronary Smooth Muscle Cells Internalize Versican-Modified LDL Through LDL Receptor-Related Protein and LDL Receptors Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 387 - 393. [Abstract] [Full Text] [PDF]

				S. W. Sakr, R. J. Eddy, H. Barth, F. Wang, S. Greenberg, F. R. Maxfield, and I. Tabas The Uptake and Degradation of Matrix-bound Lipoproteins by Macrophages Require an Intact Actin Cytoskeleton, Rho Family GTPases, and Myosin ATPase Activity J. Biol. Chem., September 28, 2001; 276(40): 37649 - 37658. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Llorente-Cortés, V. Articles by Badimon, L. Search for Related Content PubMed PubMed Citation Articles by Llorente-Cortés, V. Articles by Badimon, L. Related Collections Pathophysiology